In line with these findings, our results demonstrated that PD-L1 positive (CPS ≥ 1%) gastric cancer was associated with an improved survival outcome with nivolumab, confirming the predictive value of tumor PD-L1 expression. Here, CD274 is linked to gastric cancer.